HRP20100654T1 - Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata - Google Patents
Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata Download PDFInfo
- Publication number
- HRP20100654T1 HRP20100654T1 HR20100654T HRP20100654T HRP20100654T1 HR P20100654 T1 HRP20100654 T1 HR P20100654T1 HR 20100654 T HR20100654 T HR 20100654T HR P20100654 T HRP20100654 T HR P20100654T HR P20100654 T1 HRP20100654 T1 HR P20100654T1
- Authority
- HR
- Croatia
- Prior art keywords
- disorders
- pain
- disorder
- disease
- migraine
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 239000003825 glutamate receptor antagonist Substances 0.000 title 1
- 125000004585 polycyclic heterocycle group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 49
- 208000035475 disorder Diseases 0.000 claims 44
- 208000002193 Pain Diseases 0.000 claims 20
- 208000019695 Migraine disease Diseases 0.000 claims 14
- 206010027599 migraine Diseases 0.000 claims 14
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 208000019901 Anxiety disease Diseases 0.000 claims 10
- 230000036506 anxiety Effects 0.000 claims 10
- 206010015037 epilepsy Diseases 0.000 claims 10
- 201000000980 schizophrenia Diseases 0.000 claims 10
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 8
- 206010012335 Dependence Diseases 0.000 claims 6
- 208000030507 AIDS Diseases 0.000 claims 5
- 206010002383 Angina Pectoris Diseases 0.000 claims 5
- 206010002660 Anoxia Diseases 0.000 claims 5
- 241000976983 Anoxia Species 0.000 claims 5
- 206010003805 Autism Diseases 0.000 claims 5
- 208000020706 Autistic disease Diseases 0.000 claims 5
- 206010004663 Biliary colic Diseases 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 5
- 208000000094 Chronic Pain Diseases 0.000 claims 5
- 206010012289 Dementia Diseases 0.000 claims 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 5
- 201000010374 Down Syndrome Diseases 0.000 claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 5
- 208000010412 Glaucoma Diseases 0.000 claims 5
- 201000005569 Gout Diseases 0.000 claims 5
- 206010019196 Head injury Diseases 0.000 claims 5
- 208000023105 Huntington disease Diseases 0.000 claims 5
- 208000013016 Hypoglycemia Diseases 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 206010065390 Inflammatory pain Diseases 0.000 claims 5
- 208000008930 Low Back Pain Diseases 0.000 claims 5
- 208000036626 Mental retardation Diseases 0.000 claims 5
- 208000012902 Nervous system disease Diseases 0.000 claims 5
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 5
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims 5
- 208000004550 Postoperative Pain Diseases 0.000 claims 5
- 206010038419 Renal colic Diseases 0.000 claims 5
- 206010039966 Senile dementia Diseases 0.000 claims 5
- 208000006011 Stroke Diseases 0.000 claims 5
- 206010044688 Trisomy 21 Diseases 0.000 claims 5
- 230000001154 acute effect Effects 0.000 claims 5
- 208000005298 acute pain Diseases 0.000 claims 5
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 5
- 230000007953 anoxia Effects 0.000 claims 5
- 206010003246 arthritis Diseases 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 5
- 235000019788 craving Nutrition 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims 5
- 208000037906 ischaemic injury Diseases 0.000 claims 5
- 230000005906 menstruation Effects 0.000 claims 5
- 208000004296 neuralgia Diseases 0.000 claims 5
- 230000002981 neuropathic effect Effects 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 201000001119 neuropathy Diseases 0.000 claims 5
- 230000007823 neuropathy Effects 0.000 claims 5
- 208000020016 psychiatric disease Diseases 0.000 claims 5
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 5
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 claims 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60896004P | 2004-02-18 | 2004-02-18 | |
| PCT/US2005/004774 WO2006014185A1 (fr) | 2004-02-18 | 2005-02-15 | Composes heteropolycycliques supplementaires et leur utilisation comme antagonistes du recepteur metabotropique du glutamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100654T1 true HRP20100654T1 (hr) | 2011-01-31 |
Family
ID=35447957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100654T HRP20100654T1 (hr) | 2004-02-18 | 2010-11-29 | Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US7585881B2 (fr) |
| EP (2) | EP1723144B1 (fr) |
| JP (1) | JP4912157B2 (fr) |
| CN (2) | CN1984907A (fr) |
| AT (1) | ATE483706T1 (fr) |
| AU (1) | AU2005270208A1 (fr) |
| BR (1) | BRPI0507497A (fr) |
| CA (1) | CA2555566A1 (fr) |
| CY (1) | CY1110965T1 (fr) |
| DE (1) | DE602005023963D1 (fr) |
| DK (1) | DK1723144T3 (fr) |
| ES (1) | ES2352110T3 (fr) |
| HK (1) | HK1099285A1 (fr) |
| HR (1) | HRP20100654T1 (fr) |
| IL (1) | IL177394A0 (fr) |
| NO (1) | NO20063599L (fr) |
| NZ (1) | NZ548954A (fr) |
| PL (1) | PL1723144T3 (fr) |
| PT (1) | PT1723144E (fr) |
| RS (1) | RS51516B (fr) |
| RU (1) | RU2370495C2 (fr) |
| SG (1) | SG146657A1 (fr) |
| SI (1) | SI1723144T1 (fr) |
| UA (1) | UA84318C2 (fr) |
| UY (1) | UY28766A1 (fr) |
| WO (1) | WO2006014185A1 (fr) |
| ZA (1) | ZA200606551B (fr) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2352568C9 (ru) * | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| CN1942457A (zh) * | 2004-04-20 | 2007-04-04 | 默克公司 | 作为β－促分泌酶抑制剂用于阿尔茨海默氏病的治疗中的1,3,5－取代的苯基衍生化合物 |
| WO2006080533A1 (fr) * | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | Dérivé de 3-amino-1,2,4-triazole |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
| TW200811157A (en) | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
| TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| WO2008014199A2 (fr) * | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Composés modulant le récepteur cb2 |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| TWI443090B (zh) * | 2007-05-25 | 2014-07-01 | Abbvie Deutschland | 作為代謝性麩胺酸受體２（ｍｇｌｕ２ 受體）之正向調節劑之雜環化合物 |
| US20100144756A1 (en) * | 2007-07-13 | 2010-06-10 | Bolea Christelle | Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors |
| KR20100090777A (ko) * | 2007-10-19 | 2010-08-17 | 아스트라제네카 아베 | 대사성 글루타메이트 수용체 (ｍｇｌｕｒ)의 조절제로서의 테트라졸 유도체 |
| WO2009054785A1 (fr) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Dérivés d'éther de 1,2,4-triazole comme modulateurs de mglur5 |
| WO2009054786A1 (fr) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Dérivés de n-oxydes d'aryle 1,2,4-triazole utilisés en tant que modulateurs de mglur5 |
| CA2704684A1 (fr) * | 2007-11-07 | 2009-05-14 | Boehringer Ingelheim International Gmbh | Composes modulant le recepteur cb2 |
| AU2009223833A1 (en) * | 2008-03-03 | 2009-09-17 | Stiefel Laboratories, Inc. | Processes for preparing enantiomerically pure diol and dioxolane compounds |
| PT2291080E (pt) | 2008-05-14 | 2015-10-30 | Scripps Research Inst | Novos modelamodeladores dos recetores da esfingosina fosfato |
| JP5749162B2 (ja) * | 2008-07-10 | 2015-07-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ２受容体を調節するスルホン化合物 |
| BRPI0917465A2 (pt) * | 2008-08-12 | 2017-04-04 | Astrazeneca Ab | composto, formulação farmacêutica, uso de um composto, método para tratamento ou prevenção de um distúrbio, e, processo para preparar um composto |
| US20110224261A1 (en) * | 2008-08-12 | 2011-09-15 | Astrazeneca Ab | Crystalline form of 4-(5--4-methyl-4h-1,2,4-triazol-3-yl)pyridine |
| CN102164917A (zh) | 2008-09-25 | 2011-08-24 | 贝林格尔.英格海姆国际有限公司 | 选择性调节cb2受体的磺酰基化合物 |
| US20110306768A1 (en) * | 2008-12-18 | 2011-12-15 | Astrazeneca Ab | Processes for the manufacture of 3--pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-l,2,4-triazole, and (1r)-1-[2-(3-methylphenyl)-2h-tetrazol-5-yl]ethanol |
| US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
| WO2010096371A2 (fr) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Composés hétérocycliques qui modulent le récepteur cb2 |
| US20120029190A1 (en) * | 2009-04-03 | 2012-02-02 | Douglas Burdi | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
| CA2764339A1 (fr) | 2009-06-05 | 2010-12-09 | Oslo University Hospital Hf | Derives d'azole en tant qu'inhibiteurs de la voie wnt |
| US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| US8383615B2 (en) | 2009-06-16 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Azetidine 2-carboxamide derivatives which modulate the CB2 receptor |
| US8383651B2 (en) * | 2009-09-22 | 2013-02-26 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
| BR112012011430A8 (pt) | 2009-11-13 | 2017-12-26 | Celgene Int Ii Sarl | Compostos moduladores de receptor de esfingosina 1 fosfato e composições farmacêuticas |
| EP3868377A1 (fr) * | 2009-11-13 | 2021-08-25 | Receptos Llc | Modulateurs sélectifs du récepteur de sphingosine-1-phosphate et procédés de synthèse chirale |
| MY169497A (en) * | 2009-11-13 | 2019-04-15 | Celgene Int Ii Sarl | Selective heterocyclic sphingosine 1 phosphate receptor modulators |
| EP2519521B1 (fr) | 2009-12-29 | 2013-11-20 | Eli Lilly and Company | Composés tétrahydrotriazolopyridine comme potentialisateurs sélectifs du récepteur mglu5 utiles pour le traitement de la schizophrénie |
| CN101712641B (zh) * | 2009-12-29 | 2013-05-08 | 江苏工业学院 | 一种甲硫基苯甲酸的制备方法 |
| EP2523936A1 (fr) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Composés qui modulent le récepteur cb2 |
| EP2531510B1 (fr) | 2010-02-01 | 2014-07-23 | Novartis AG | Dérivés de pyrazolo[5,1-b]utilisés en tant qu'antagonistes du récepteur de crf-1 |
| WO2011092293A2 (fr) | 2010-02-01 | 2011-08-04 | Novartis Ag | Dérivés de cyclohexylamide utilisés en tant qu'antagonistes du récepteur du crf |
| US8835444B2 (en) | 2010-02-02 | 2014-09-16 | Novartis Ag | Cyclohexyl amide derivatives as CRF receptor antagonists |
| US8329735B2 (en) | 2010-03-05 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the CB2 receptor |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2560488B1 (fr) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Aminopyridines et aminotriazines, leurs compositions et leurs procédés d'utilisation |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| WO2012012307A1 (fr) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Composés sulfonylés qui modulent le récepteur cb2 |
| EP2632900A2 (fr) * | 2010-10-28 | 2013-09-04 | Merck Sharp & Dohme Corp. | Modulateurs caprolactames des récepteurs mglur5 |
| JP2013544874A (ja) | 2010-12-08 | 2013-12-19 | オスロ ユニヴァーシティー ホスピタル エイチエフ | Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体 |
| DE102010063974B4 (de) * | 2010-12-22 | 2021-10-07 | Thomas Rühl | Pharmakologische Wirkstoffe und Radiodiagnostika mit 18F-markierter 3-Aryl- oder 3-Heteroaryl-1,2,4-oxadiazoleinheit und Verfahren zu deren Herstellung |
| CN103561740A (zh) | 2011-03-18 | 2014-02-05 | 诺瓦提斯公司 | 用于帕金森病中多巴胺诱导的运动障碍的α7烟碱性乙酰胆碱受体活化剂和mGluR5拮抗剂的组合 |
| US8759380B2 (en) * | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| JP6129159B2 (ja) | 2011-05-13 | 2017-05-17 | レセプトス エルエルシー | 選択的複素環式スフィンゴシン１−リン酸受容体モジュレーター |
| EP2545964A1 (fr) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Nouveaux composés se liant au fxr (nr1 h4) et modulant son activité |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP2803668A1 (fr) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles |
| AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
| BR112017018992B1 (pt) * | 2015-03-05 | 2022-02-08 | Bayer Cropscience Aktiengesellschaft | Processo de preparação de derivados de fenilisoxazolina substituída |
| WO2016142886A2 (fr) * | 2015-03-10 | 2016-09-15 | Aurigene Discovery Technologies Limited | Composés 3-substitué -1,2,4-oxadiazole et thiadiazole utilisés comme immunomodulateurs |
| MX2020003735A (es) | 2015-03-10 | 2022-01-14 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores. |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836A1 (fr) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Composes modulant fxr (nr1h4) |
| WO2018183193A1 (fr) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Combinaisons thérapeutiques pour le traitement de maladies du foie |
| WO2019061324A1 (fr) | 2017-09-29 | 2019-04-04 | Curis Inc. | Formes cristallines d'immunomodulateurs |
| EA202090871A1 (ru) | 2017-10-06 | 2020-07-03 | Форма Терапьютикс, Инк. | Ингибирование убиквитин-специфической пептидазы 30 |
| EA202090536A1 (ru) | 2017-10-11 | 2020-07-22 | Ориджен Дискавери Текнолоджис Лимитед | Кристаллические формы 3-замещенного 1,2,4-оксадиазола |
| SG11202003625VA (en) | 2017-11-03 | 2020-05-28 | Aurigene Discovery Tech Ltd | Dual inhibitors of tim-3 and pd-1 pathways |
| WO2019087092A1 (fr) | 2017-11-06 | 2019-05-09 | Aurigene Discovery Technologies Limited | Thérapies conjointes à des fins d'immunomodulation |
| CN111448181B (zh) * | 2017-11-16 | 2023-05-19 | 蒙特多力士有限公司 | 单脒和二脒核酸内切-外切酶抑制剂和抑制核酸内切-外切酶活性的方法 |
| CN112513036B (zh) | 2018-05-17 | 2024-05-24 | 福马治疗有限公司 | 用作泛素特异性肽酶30抑制剂的稠合双环化合物 |
| AU2019356011A1 (en) | 2018-10-05 | 2021-04-01 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
| WO2020150136A1 (fr) | 2019-01-15 | 2020-07-23 | Gilead Sciences, Inc. | Composés modulateurs de fxr (nr1h4) |
| CN118388473A (zh) | 2019-02-19 | 2024-07-26 | 吉利德科学公司 | Fxr激动剂的固体形式 |
| CA3139063A1 (fr) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Inhibiteurs de kcnt1 et procedes d'utilisation |
| WO2021142006A1 (fr) * | 2020-01-07 | 2021-07-15 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 |
| TW202334117A (zh) | 2020-08-24 | 2023-09-01 | 美商達薩瑪治療公司 | Ｓａｒｍ１之抑制劑 |
| WO2022231872A1 (fr) * | 2021-04-29 | 2022-11-03 | Praxis Precision Medicines, Inc. | Inhibiteurs de kcnt1 et méthodes d'utilisation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4538833A (en) * | 1983-12-08 | 1985-09-03 | P I E International Inc. | Publication |
| US5403138A (en) * | 1991-10-09 | 1995-04-04 | Fuji Photo Film Co., Ltd. | Booklet album including a double-sided photograph and a method of making the same |
| US5332265A (en) * | 1993-01-22 | 1994-07-26 | Minnesota Mining And Manufacturing Company | Advertising assembly |
| UA75871C2 (en) | 1999-08-19 | 2006-06-15 | Nps Pharma Inc | 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors |
| AU2002360621B2 (en) | 2001-12-19 | 2007-01-25 | Merck & Co., Inc. | heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 |
| RU2352568C9 (ru) * | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
| AU2003264018A1 (en) * | 2002-08-09 | 2004-02-25 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| WO2004014370A2 (fr) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Nouveaux composes |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| UY29796A1 (es) * | 2005-09-29 | 2007-04-30 | Astrazeneca Ab | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor |
-
2005
- 2005-02-09 US US11/053,752 patent/US7585881B2/en not_active Expired - Fee Related
- 2005-02-15 AU AU2005270208A patent/AU2005270208A1/en not_active Abandoned
- 2005-02-15 PL PL05802855T patent/PL1723144T3/pl unknown
- 2005-02-15 SI SI200531175T patent/SI1723144T1/sl unknown
- 2005-02-15 RS RSP-2010/0525A patent/RS51516B/en unknown
- 2005-02-15 WO PCT/US2005/004774 patent/WO2006014185A1/fr active Application Filing
- 2005-02-15 BR BRPI0507497-5A patent/BRPI0507497A/pt not_active IP Right Cessation
- 2005-02-15 DK DK05802855.6T patent/DK1723144T3/da active
- 2005-02-15 EP EP05802855A patent/EP1723144B1/fr active Active
- 2005-02-15 PT PT05802855T patent/PT1723144E/pt unknown
- 2005-02-15 RU RU2006128446/04A patent/RU2370495C2/ru not_active IP Right Cessation
- 2005-02-15 UA UAA200608867A patent/UA84318C2/ru unknown
- 2005-02-15 DE DE602005023963T patent/DE602005023963D1/de active Active
- 2005-02-15 CN CNA2005800043063A patent/CN1984907A/zh active Pending
- 2005-02-15 NZ NZ548954A patent/NZ548954A/xx unknown
- 2005-02-15 EP EP10182161A patent/EP2311830A1/fr not_active Withdrawn
- 2005-02-15 SG SG200806914-8A patent/SG146657A1/en unknown
- 2005-02-15 CA CA002555566A patent/CA2555566A1/fr not_active Abandoned
- 2005-02-15 ES ES05802855T patent/ES2352110T3/es active Active
- 2005-02-15 US US10/588,702 patent/US20070179188A1/en not_active Abandoned
- 2005-02-15 JP JP2006554165A patent/JP4912157B2/ja not_active Expired - Fee Related
- 2005-02-15 AT AT05802855T patent/ATE483706T1/de active
- 2005-02-15 CN CNA2007101278476A patent/CN101096368A/zh active Pending
- 2005-02-18 UY UY28766A patent/UY28766A1/es not_active Application Discontinuation
-
2006
- 2006-08-07 ZA ZA200606551A patent/ZA200606551B/en unknown
- 2006-08-08 NO NO20063599A patent/NO20063599L/no not_active Application Discontinuation
- 2006-08-09 IL IL177394A patent/IL177394A0/en unknown
-
2007
- 2007-05-22 HK HK07105399.9A patent/HK1099285A1/xx not_active IP Right Cessation
- 2007-08-18 US US11/840,953 patent/US20080045571A1/en not_active Abandoned
- 2007-08-18 US US11/840,955 patent/US20080015204A1/en not_active Abandoned
- 2007-08-18 US US11/840,952 patent/US20080015234A1/en not_active Abandoned
- 2007-08-18 US US11/840,954 patent/US20070293545A1/en not_active Abandoned
-
2010
- 2010-11-29 HR HR20100654T patent/HRP20100654T1/hr unknown
- 2010-12-03 CY CY20101101116T patent/CY1110965T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100654T1 (hr) | Dodatni heterociklicki spojevi i njihova upotreba kao antagonista metabotropnih receptora glutamata | |
| JP2007523168A5 (fr) | ||
| JP2009510064A5 (fr) | ||
| HRP20140451T1 (hr) | Derivati izoksazola i njihova uporaba kao pojaäśivaäśa metabotropnih glutamatnih receptora | |
| HRP20120909T4 (hr) | Derivati oksadiazola i njihova uporaba kao pojaäśivaäśa-842 metabotropnih glutamatnih receptora | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| HRP20110524T1 (hr) | Spojevi dihidropiridina za neurodegenerativne bolesti i demenciju | |
| RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
| JP2020503323A5 (fr) | ||
| WO2006017409A3 (fr) | Antagonistes de nmda/nr2b à base d'hétéroaryles 1,3-disubstitués | |
| WO2008107480A8 (fr) | Dérivés de 3-cyano-pyridone 1,4 disubstitués et leur utilisation comme modulateurs positifs des récepteurs mglur2 | |
| MX2010005753A (es) | Derivados de isoxazolo-pirazina. | |
| HRP20141116T1 (hr) | 1h-kinazolin-2,4-dioni | |
| JP2009515934A5 (fr) | ||
| PA8597301A1 (es) | Derivados de imidazol-4-il-etinil-piridina | |
| HRP20120876T1 (hr) | Brzo disocirajuä†i antagonisti dopamin 2 receptora | |
| JP2013523846A5 (fr) | ||
| TW200635906A (en) | Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine | |
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| RS20050892A (en) | Imidazole derivatives as glutamate receptor antagonists | |
| HRP20201412T1 (hr) | Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda | |
| JP2005524696A5 (fr) | ||
| WO2007135131A8 (fr) | Dérivés de pyrazinone substitués à utiliser comme médicament | |
| JP2004524357A5 (fr) | ||
| WO2009078432A1 (fr) | Composé 1-alkyl-4-amino-1h-pyrazole-3-carboxamide |